Microcystic inner nuclear layer abnormalities and neuromyelitis optica

JAMA Neurology

Volumn 70, Issue 5, 2013, Pages 629-633

  Gelfand, Jeffrey M ^a   Cree, Bruce A ^a   Nolan, Rachel ^a   Arnow, Sam ^a   Green, Ari J ^a,b  

^a UCSF Multiple Sclerosis Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; COLOR VISION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MEDICAL HISTORY; MICROCYSTIC INNER NUCLEAR LAYER ABNORMALITY; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OPTIC NEURITIS; PRIORITY JOURNAL; RETINAL NERVE FIBER LAYER THICKNESS; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY;

EID: 84877743896     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1832     Document Type: Article

References (42)

1. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep. 2008;8(5):427-433.
2. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol. 2007;187(1-2):126-138. (Pubitemid 47007701)
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106-2112. (Pubitemid 39626806)
4. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(pt 5):1194-1205. (Pubitemid 47355941)
5. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66(5):630-643.
6. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012;11(6):535-544.
7. Li J, Patil RV, Verkman AS. Mildly abnormal retinal function in transgenic mice without Müller cell aquaporin-4 water channels. Invest Ophthalmol Vis Sci. 2002;43(2):573-579. (Pubitemid 34113244)
8. Pannicke T, Wurm A, Iandiev I, et al. Deletion of aquaporin-4 renders retinal glial cells more susceptible to osmotic stress. J Neurosci Res. 2010;88(13):2877-2888.
9. McKeon A, Fryer JP, Apiwattanakul M, et al. Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol. 2009;66(9):1134-1138.
10. Magaña SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol. 2009;66(8):964-966.
11. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993;34(2):162-168. (Pubitemid 23223043)
12. de Seze J, Blanc F, Jeanjean L, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008;65(7):920-923. (Pubitemid 352008475)
13. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009;73(4):302-308.
14. Naismith RT, Tutlam NT, Xu J, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009;72(12):1077-1082.
15. Green AJ, Cree BA. Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry. 2009;80(9):1002-1005.
16. Monteiro MLR, Fernandes DB, Apóstolos-Pereira SL, Callegaro D. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53(7):3959-3966.
17. Syc SB, Saidha S, Newsome SD, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135(pt 2):521-533.
18. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol. 2008;126(1):12-16.
19. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114(4):810-815.
20. Fernandes DB, Ramos RdeI, Falcochio C, Apóstolos-Pereira S, Callegaro D, Monteiro ML. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol. 2012;32(2):102-106.
21. Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain. 2012;135(pt 6):1786-1793.
22. Saidha S, Sotirchos ES, Ibrahim MA, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study [published correction appears in Lancet Neurol. 2012;11(12):1021]. Lancet Neurol. 2012;11(11):963-972.
23. Vanburen JM. Trans-synaptic retrograde degeneration in the visual system of primates. J Neurol Neurosurg Psychiatry. 1963;26:402-409.
24. Gills JPJ Jr, Wadsworth JA. Degeneration of the inner nuclear layer of the retina following lesions of the optic nerve. Trans Am Ophthalmol Soc. 1966;64:66-88.
25. Gills JPJ, Wadsworth JAC. Retrograde transsynaptic degeneration of the inner nuclear layer of the retina. Invest Ophthalmol Vis Sci. 1967;6(4):437-448.
26. Balk LJ, Killestein J, Polman CH, Uitdehaag BMJ, Petzold A. Microcystic macular oedema confirmed, but not specific for multiple sclerosis. Brain. 2012;135(pt 12):e226-author reply e227.
27. Darby JE, Carr RA, Beazley LD. Retinal ganglion cell death during regeneration of the frog optic nerve is not accompanied by appreciable cell loss from the inner nuclear layer. Anat Embryol (Berl). 1990;182(5):487-492. (Pubitemid 20369765)
28. Komáromy AM, Brooks DE, Källberg ME, et al. Long-term effect of retinal ganglion cell axotomy on the histomorphometry of other cells in the porcine retina. J Glaucoma. 2003;12(4):307-315. (Pubitemid 37169650)
29. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489. (Pubitemid 43958540)
30. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
31. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012;7(5):e36847.
32. Villoslada P, Cuneo A, Gelfand J, Hauser SL, Green A. Color vision is strongly associated with retinal thinning in multiple sclerosis. Mult Scler. 2012;18(7):991-999.
33. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing Snellen visual acuity measurements. Retina. 2010;30(7):1046-1050.
34. Abegg M, Zinkernagel M, Wolf S. Microcystic macular degeneration from optic neuropathy. Brain. 2012;135(pt 12):e225.
35. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol. 2007;245(5):627-636. (Pubitemid 46951227)
36. Da T, Verkman AS. Aquaporin-4 gene disruption in mice protects against impaired retinal function and cell death after ischemia. Invest Ophthalmol Vis Sci. 2004;45(12):4477-4483. (Pubitemid 39564674)
37. Papeix C, Vidal JS, de Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256-259. (Pubitemid 46592781)
38. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67(8):1016-1017.
39. Kleiter I, Hellwig K, Berthele A, et al Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69(2):239-245.
40. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53(5):1107-1114. (Pubitemid 29442132)
41. Collongues N, Marignier R, Zéphir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology. 2010;75(12):1084-1088.
42. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.